Navigation Links
RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster

LEXINGTON, Mass., Sept. 29 /PRNewswire-FirstCall/ -- RainDance Technologies announced today the launch of the dScreen Consortium, a research initiative conducted with sanofi-aventis, Paris (EURONEXT: SAN and NYSE: SNY), and Louis Pasteur University of Strasbourg, France, to develop the next generation of high-throughput screening (HTS) for drug discovery applications. The consortium was founded with the assistance of the ALSACE BIOVALLEY(TM) cluster, France, which helped secure financing and support for the program. The expected gains in terms of productivity and knowledge should accelerate the drug discovery programs.

The dScreen Consortium assembles the renowned drug screening expertise of sanofi-aventis, the unique expertise in droplet-based micro reactors of the Chemical Biology Laboratory at the Institute for Science and Supramolecular Engineering (ISIS) in Louis Pasteur University, and RainDance Technologies' unique capabilities to apply droplet-based microfluidic technologies to human health and disease research.

"We are delighted to enter this partnership with two highly innovative research groups in this rapidly advancing field," said Martin Galvan Ph.D., Scientific Director at the sanofi-aventis research site in Strasbourg. "The expected gains in terms of productivity and knowledge should significantly accelerate our drug discovery programs."

Based in the Alsace Biovalley in Strasbourg, the consortium will utilize the picoliter volumes and ultra-high-speed capabilities of RainDance's technology and systems to achieve breakthrough performance in high-throughput drug screening methodologies.

"This exciting project represents the first research collaboration undertaken by our new RainDance Technologies France SARL subsidiary," said Chris McNary, President and Chief Executive Officer of RainDance Technologies. "The simplicity, speed and minute volume of our technology replace current complex automation solutions in high-throughput screening. Our technology will process 10 million droplets per hour on a single benchtop instrument, dramatically accelerating the drug discovery process while conserving precious screening compounds," added McNary.

"This project is an excellent opportunity to develop the compartmentalisation of reactions in emulsion droplets for an entirely new field of application: HTS for drug discovery," said Andrew Griffiths, head of the Chemical Biology Laboratory at ISIS.

"The dScreen Consortium is a great illustration of the 'Pole de Competitivite' policy in France: the development of breakthrough innovations in drug screening through collaborative R&D programs results in strengthening local actors such as the sanofi-aventis research site and in the creation of a U.S. subsidiary company in Alsace. Furthermore, the establishment of a drug screening services platform based on the results of the program will reinforce the capabilities of our cluster," said Pascal Neuville, President of ALSACE BIOVALLEY.

More about dScreen

The aim is to develop a digital microfluidic system for quantitative HTS of bio-active compounds using purified targets and cell-based assays. The very high-throughput will enable the measurement of dose-response curves for every compound in a chemical library. The second objective is to develop a new system for compound storage in which each compound will be stored in droplets using a microfluidic device.

About the ALSACE BIOVALLEY(TM) cluster

The ALSACE BIOVALLEY(TM) cluster's mission is to bring together and support the development and growth of all public and private players involved in the sector of life sciences and healthcare in Alsace. The ALSACE BIOVALLEY(TM) cluster brings together the main organizations supporting the field of life science in Alsace, thus granting all its players a simplified, more efficient and rationalized access to the entire pool of regional resources and skills.

The ALSACE BIOVALLEY(TM) cluster claims to be a genuine project catalyst and to hold the position of one of the main European clusters, offering entry into the unique network of excellence provided by the trinational Biovalley cluster (Alsace, Basel and Freiburg region).

About RainDance Technologies, Inc.

RainDance Technologies Inc. is a provider of innovative droplet-based microfluidic solutions for human health and disease research. The speed and simplicity of the company's exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company's technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance's initial application will focus on the targeted resequencing of the human genome -- one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information, please visit

About Louis Pasteur University

Louis Pasteur University (ULP, Strasbourg, France --, founding partner of EUCOR (European Federation of Universities of the Upper Rhine), is a member of the League of European Research Universities (LERU, A strong partnership also exists with the main French research institutions (CNRS, INSERM and INRA).

In the field of contract-based research with private companies, ULP has (since 1987) already set up a department for industrial relations and technology transfer (ULP-Industrie), which provides efficient support for the scientists.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward-looking statements -- sanofi-aventis

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2007. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Steven Becker

SOURCE RainDance Technologies
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. RainDance Dedicates New Headquarters, Manufacturing Facility
2. RainDance Technologies to Dedicate New Headquarters, Manufacturing Facility in Lexington
3. RainDance and Scripps to Collaborate on Targeted Sequencing for Wellderly Study
4. RainDance Technologies Appoints Olex Vice President, System Development
5. RainDance Appoints Kelly Chief Operating Officer
6. RainDance Announces Company Relocation and Manufacturing Startup
7. RainDance Appoints Becker Chief Commercial Officer
8. RainDance Technologies Appoints McNary President and CEO
9. Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition
10. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
11. Spherics, Inc. Presented Three Key Technologies (BIOROD(TM), BIOGIT(TM), and SPHEROMER(TM)) at the 35th Annual Meeting of Controlled Release Society
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) ... USGA Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes ... with turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of ...
(Date:11/24/2015)... Florida (PRWEB) , ... November 24, 2015 , ... ... biggest event of the year and one of the premier annual events for ... and ran from 8–11 November 2015, where ISPE hosted the largest number of ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics ... (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View (FPV) ... Many AMA members have embraced this type of racing and several new model aviation ...
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/12/2015)... Mass. , Nov. 12, 2015  Arxspan ... Institute of MIT and Harvard for use of ... discovery information management tools. The partnership will support ... both biological and chemical research information internally and ... will be used for managing the Institute,s electronic ...
(Date:11/11/2015)... 11, 2015   MedNet Solutions , an innovative SaaS-based ... research, is pleased to announce that it will be a ... event, to be held November 17-19 in ... live demonstrations of iMedNet , MedNet,s easy-to-use, ... iMedNet has been able to deliver time and cost ...
Breaking Biology News(10 mins):